22/09/2020 3:55 am Welcome to isteroids.com - BLOG

Thursday 22, Apr 2010

  Canakinumab effective for Systemic Juvenile Idiopathic Arthritis

Posted By
Pin it Share on Tumblr

Canakinumab effective for Systemic Juvenile Idiopathic ArthritisA new interleukin-1 (IL-1)-beta blocking monoclonal antibody, Canakinumab (ACZ885), has shown encouraging effectiveness besides being well tolerated in children suffering with systemic juvenile idiopathic arthritis (sJIA).

This finding was revealed by a new phase II study presented at PReS 2009, a joint congress with the 2009 Congress of the European League against Rheumatism (EULAR) in Copenhagen, Denmark.

Dr Nicolino Ruperto, Senior Scientist of PRINTO (Paediatric Rheumatology International Trials Organization), an international not-for-profit research network managing trials of children with rheumatic diseases, said JIA (juvenile idiopathic arthritis) is the most common chronic inflammatory disease of childhood affecting nearly one in 1,000 children, and sJIA is the most severe subtype.

Saturday 06, Mar 2010

  Canakinumab can prove worth in children with Systemic Juvenile Idiopathic Arthritis

Posted By
Pin it Share on Tumblr

Canakinumab can prove worth in children with Systemic Juvenile Idiopathic ArthritisA new interleukin-1 (IL-1)-beta blocking monoclonal antibody, Canakinumab (ACZ885), was recently found to be an effective option to encourage effectiveness besides being well tolerated in children with sJIA (systemic juvenile idiopathic arthritis).

This finding was disclosed in a phase II study presented at PReS 2009, a joint congress with the 2009 Congress of the European League against Rheumatism (EULAR) in Copenhagen, Denmark.

JIA is considered to be one of the most common chronic inflammatory diseases of childhood that affects approximately 1 in every 1,000 children. sJIA is the most severe subtype of JIA.